NCT03328273 2026-04-20
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT03462342 2026-04-13
CAPRI
University of Pennsylvania
Phase 2 Completed
NCT04704661 2026-04-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06732401 2026-04-13
CLEAR
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03878095 2026-04-08
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06769126 2026-03-30
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Phase 2 Recruiting